1249 related articles for article (PubMed ID: 15304466)
1. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
3. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
4. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
6. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
Maroo A; Lincoff AM
Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
9. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
13. Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
Doggrell S
Expert Opin Pharmacother; 2003 Aug; 4(8):1431-3. PubMed ID: 12877649
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Summers KM; Holdford DA; Crouch MA
Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
16. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Gurm HS; Sarembock IJ; Kereiakes DJ; Young JJ; Harrington RA; Kleiman N; Feit F; Wolski K; Bittl JA; Wilcox R; Topol EJ; Lincoff AM
J Am Coll Cardiol; 2005 Jun; 45(12):1932-8. PubMed ID: 15963389
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
19. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Chacko M; Lincoff AM; Wolski KE; Cohen DJ; Bittl JA; Lansky AJ; Tsuchiya Y; Betriu A; Yen MH; Chew DP; Cho L; Topol EJ
Am Heart J; 2006 May; 151(5):1032.e1-7. PubMed ID: 16644331
[TBL] [Abstract][Full Text] [Related]
20. Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
Robertson JO; Lincoff AM; Wolski K; Topol EJ
Am J Cardiol; 2006 Jun; 97(12):1679-84. PubMed ID: 16765113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
